Andersson D E, Röjdmark S
Horm Metab Res. 1984 Dec;16 Suppl 1:160-3. doi: 10.1055/s-2007-1014923.
The current study was performed in order to investigate whether verapamil would affect the basal blood glucose concentration in a metabolic state characterized by an increased hepatic gluconeogenesis. For that purpose verapamil (5 mg/h) was infused i.v. during three hours in a group of healthy subjects fasted for 36 h, and for comparison also in healthy subjects fasted overnight. Verapamil was found to lower the basal blood glucose concentration in the 36 h fasted subjects. No effect of verapamil was seen in the overnight-fasted group. Since both the insulin and the glucagon concentrations remained unaffected by verapamil after the 36 h fast, other glucose-regulatory factors must have been responsible for the blood glucose lowering effect of the drug. An effect upon the cytosolic calcium concentration in the hepatocytes causing a decrease in the hepatic gluconeogenesis, is a feasible mechanism by which verapamil might have lowered the blood glucose concentration in the individuals subjected to a prolonged fast.
进行本研究是为了调查维拉帕米是否会影响以肝糖异生增加为特征的代谢状态下的基础血糖浓度。为此，在一组禁食36小时的健康受试者中静脉输注维拉帕米（5毫克/小时），持续3小时，作为对照，也在隔夜禁食的健康受试者中进行输注。结果发现，维拉帕米可降低禁食36小时受试者的基础血糖浓度。在隔夜禁食组中未观察到维拉帕米的作用。由于禁食36小时后，胰岛素和胰高血糖素浓度均未受维拉帕米影响，因此，一定是其他葡萄糖调节因子导致了该药物的血糖降低作用。维拉帕米可能通过影响肝细胞胞质钙浓度，导致肝糖异生减少，进而降低长期禁食个体的血糖浓度，这是一种可行的机制。
